Investors

Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.
 

More »
Recent News
DateTitle 
12/05/18
SOUTH SAN FRANCISCO, Calif. , Dec. 5, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's executive vice president and chief financial officer, is scheduled to present a company overview at the BMO Capital Markets 2018 Prescriptions for
11/06/18
Reports TAVALISSE™ (fostamatinib disodium hexahydrate) net product sales of $4.9 million Conference call and webcast today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today reported financial results for the third
11/01/18
Data related to fostamatinib accepted for oral presentation and two poster presentations SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2018 /PRNewswire/ --  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that two-year safety and efficacy data from its FIT Phase 3 extension study (FIT3) for the

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)
Volume
Data as of
More »
Upcoming Events
More events are coming soon.
What's New

E-mail Alerts

Click here to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site